Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ENX-104 in Participants With Major Depressive Disorder With Anhedonia

NCT07253324 is registered in ClinicalTrials.gov with Engrail Therapeutics INC as lead sponsor.

NCT NCT07253324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07253324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ENX-104 in Participants With Major Depressive Disorder With Anhedonia
Lead sponsor
Engrail Therapeutics INC
Phase
Phase 1
Overall status
Completed
Start date
February 17, 2025
Completion date
November 26, 2025
Enrollment
48 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder